BCL2 and cancer: Inhibition of these BCL-2 family proteins with inhibitors has been extensively studied as a strategy for cancer treatment, resulting in the identification of ABT263 (navitoclax, a dual BCL-2 and BCL-XL inhibitor), ABT199 (venetoclax, a BCL-2 selective inhibitor), and several BCL-XL and MCL-1 monoselective inhibitors are promising anticancer drug candidates.55